DBV Technologies (DBVT) Total Non-Current Liabilities (2015 - 2026)
DBV Technologies (DBVT) posted quarterly Total Non-Current Liabilities of $8.5 million for Q2 2026, up 9.25% year-on-year from $7.8 million in Q2 2025, and up 26.87% on a QoQ basis from $6.7 million in Q1 2026.
DBV Technologies (DBVT) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
DBV Technologies (DBVT) has reported Total Non-Current Liabilities for 12 consecutive years, with $8.5 million the latest figure, recorded in Q2 2026.
- Quarterly Total Non-Current Liabilities rose 9.25% year-over-year to $8.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $8.5 million (up 9.25% YoY) and the FY2025 annual result came in at $6.9 million, down 3.29% from the prior year.
- Total Non-Current Liabilities advanced to $8.5 million in Q2 2026 per DBVT's latest filing, from $6.7 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for DBVT reached as high as $22.5 million in Q4 2022 and fell as low as $5.5 million in Q4 2023.
- A 5-year average of $10.4 million and a median of $7.9 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The largest YoY upside for Total Non-Current Liabilities was 121.92% in 2023 against a maximum downside of 75.78% in 2023.
- Year by year, Total Non-Current Liabilities stood at $22.5 million in 2022, then slumped by 75.78% to $5.5 million in 2023, then soared by 30.65% to $7.1 million in 2024, then retreated by 3.29% to $6.9 million in 2025, then rose by 23.19% to $8.5 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $8.5 million, $6.7 million, and $6.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | DBV Technologies | 267.50 Mn | 92.60 Mn | - | 8.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.50 Mn |
| Mar 31, 2026 | 6.70 Mn |
| Dec 31, 2025 | 6.90 Mn |
| Sep 30, 2025 | 8.16 Mn |
| Jun 30, 2025 | 7.78 Mn |
| Mar 31, 2025 | 7.31 Mn |
| Dec 31, 2024 | 7.14 Mn |
| Sep 30, 2024 | 8.11 Mn |
| Jun 30, 2024 | 7.71 Mn |
| Mar 31, 2024 | 7.76 Mn |
| Dec 31, 2023 | 5.46 Mn |
| Sep 30, 2023 | 14.35 Mn |
| Jun 30, 2023 | 19.91 Mn |
| Mar 31, 2023 | 21.06 Mn |
| Dec 31, 2022 | 22.54 Mn |
| Sep 30, 2022 | 7.67 Mn |
| Jun 30, 2022 | 10.13 Mn |
| Mar 31, 2022 | 9.49 Mn |
| Dec 31, 2021 | 16.05 Mn |
| Sep 30, 2021 | 20.22 Mn |